Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Urinary tract infection is the infection of bladder, urethra, ureter and kidneys and occurs due to colonization of microbial pathogen in the bladder or kidneys. There are two types of urinary tract infections: complicated urinary tract infection and uncomplicated urinary tract infection.
The global urinary tract infection treatment market is estimated to account for US$ 10,170.8 Mn in terms of value and is expected to reach US$ 11,827.8 Mn by the end of 2027.
Global Urinary Tract Infection Treatment Market: Drivers
High prevalence of urinary tract infection is expected to propel growth of the global urinary tract infection market over the forecast period. For instance, according to the study “Prevalence of Bacterial Urinary Tract Infections and Associated Factors among Patients Attending Hospitals in Bushenyi District, Uganda”, published in February 2019, the prevalence of UTI was 32.2% among the study.
Moreover, R&D of novel class of antibiotics for urinary tract infections is also expected to aid in growth of the market. For instance, in August 2020, researchers at the California Polytechnic State University reported development of a new class of antibiotics for urinary tract infections, which targets bacterial iron acquisition, at the American Chemical Society (ACS) Fall 2020 Virtual Meeting & Expo.
Quinolones held dominant position in the global urinary tract infection treatment market in 2019, accounting for 37.7% share in terms of value, followed by Cephalosporin and Penicillin & Combinations, respectively.
Figure 1. Global Urinary Tract Infection Treatment Market Share (%), by Value, by Drug Type, 2019
Global Urinary Tract Infection Treatment Market: Restraints
Complex regulatory requirements are expected to hinder growth of the global urinary tract infection treatment market. The clinical trial of an antibiotic differs from other therapeutic drugs with respect to the clinical approval approach such as clinical trial design, interpretation and analysis. The sponsor has to conduct non-inferiority trials to get the approval with along with currently registered antibacterial drugs. The clinical trials for designing antibacterial drugs is complex and require an informative, ethical and scientific approach. These factors are expected to negatively impact market growth over the forecast period.
Moreover, low investment in research & development is also expected to limit the market growth. Many companies have stopped or decreased R&D activities in developing antibiotics as it has poor return on investment. This is attributed to the duration of treatment being short and these drugs cure the disease most of the time. Only a few companies such as GlaxoSmithKline, Pfizer, Cipla are investing in antibacterial discovery programs. Low investment on R&D for new drugs is expected to hamper growth of the market over the forecast period as most bacteria are becoming resistant to currently available antibiotics.
Urinary Tract Infection Treatment Market Report Coverage
||Market Size in 2019:
||US$ 9,971.9 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 11,827.8 Mn
- North America: U.S., Canada
- Latin America: Brazil, Argentina, Mexico, Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
- Middle East: GCC Countries, Israel, Rest of Middle East
- Africa: South Africa, North Africa, Central Africa
- By Drug Type:
- Penicillin & Combinations: Amoxicillin, Amoxicillin+ Clavulanate, Potassium, Others.
- Quinolones: Ciprofloxacin, Levofloxacin, Nalidixic acid, Norfloxacin, Others.
- Cephalosporin: Ceftriaxone, Cefuroxime, Cefixime, Cephalexin.
- Aminoglycoside Antibiotics: Amikacin, Gentamicin.
- Sulphonamides (Sulfamethoxazole + Trimethoprim), Azoles and Amphotericin B, Tetracycline (Doxycycline), Nitrofurans (Nitrofurantoin), Other.
- By Disease Indication: Complicated UTI, Recurring Complicated UTI, Uncomplicated UTI, Neurogenic Bladder Infections.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Cipla Ltd., Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., Iterum Therapeutics plc, Novartis AG AstraZeneca Plc, Allecra Therapeutics, Healthy.io, Shionogi Inc., Spero Therapeutics, Inc., and Venatorx Pharmaceuticals.
- High prevalence of urinary tract infection
- Availability of number of drugs
|Restraints & Challenges:
- Complex regulatory requirements
- Low research and development
Global Urinary Tract Infection Treatment Market: Opportunities
R&D of in urinary tract infections is expected to offer lucrative growth opportunities for players in the global urinary tract infection treatment market. For instance, in May 2020, researchers from Vrije Universiteit Amsterdam, The Netherlands, reported that in an intention-to-diagnose high-risk pediatric population, urinary tract infections could be discriminated from non- urinary tract infection by volatile organic compounds profiling, using an electronic nose.
Moreover, high prevalence of urinary tract infections in emerging economies is also expected to aid in growth of the market. For instance, the study, ‘Prevalence of urinary tract infections and current scenario of antibiotic susceptibility pattern of bacteria causing UTI’ conducted at the Microbiology department of a tertiary health care hospital in Mumbai and published in 2018, the overall prevalence of UTI was 33.54% of which 66.78% were females and 33.22% were from males.
The global urinary tract infection treatment market was valued at US$ 9,971.9 Mn in 2019 and is forecast to reach a value of US$ 11,827.8 Mn by 2027 at a CAGR of 2.2% between 2020 and 2027.
Figure 2. Global Urinary Tract Infection Treatment Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027
Market Trends/Key Takeaways
Major players in the global urinary tract infection treatment market are focused on R&D of new therapies in order to expand their product portfolio. For instance, in February 2020, Allecra Therapeutics, a France-based pharmaceutical company, announced that its Exblifep (cefepime-enmetazobactam), a combination of a novel extended-spectrum beta-lactamase inhibitor, enmetazobactam, and the fourth-generation cephalosporin cefepime, achieved primary endpoints in a clinical trial for complicated urinary tract infections (cUTI).
Major players in the market are also focused on adopting partnership strategies to enhance their market share. For instance, in July 2019, Healthy.io, a smartphone camera-based solutions developer, announced an agreement with Walgreens Boots Alliance, Inc. placing Healthy.io's Dip UTI test kits in Boots pharmacies throughout the United Kingdom.
Global Urinary Tract Infection Treatment Market: Competitive Landscape
Major players operating in the global urinary tract infection treatment market include, Cipla Ltd., Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., Iterum Therapeutics plc, Novartis AG AstraZeneca Plc, Allecra Therapeutics, Healthy.io, Shionogi Inc., Spero Therapeutics, Inc., and Venatorx Pharmaceuticals.
Global Urinary Tract Infection Treatment Market: Key Developments
Major players in the global urinary tract infection treatment market are focused on R&D of new therapies in order to expand their product portfolio. For instance, in May 2020, Spero Therapeutics, Inc. announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, of tebipenem HBr for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP).